Trial Profile
An Open Label Study of the Efficacy and Safety of Re-treatments With Rituximab (MabThera/Rituxan) in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNFa Therapies
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Methotrexate; Steroids
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Roche
- 02 Apr 2014 New trial record